 |
|
|
| |
Evaluation of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions with the Pan Genotypic HCV NS3/4A Protease Inhibitor Voxilaprevir (GS-9857) or Sofosbuvir/Velpatasvir/Voxilaprevir and Phenotypic Probe Drugs
|
| |
| |
Reported by Jules Levin
17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy June 8 - 10, 2016, Washington, DC
Brian J. Kirby, James Taylor Luisa M. Stamm, Qinghua Song, Helen Wei, Yizhao Li, Dina Alhelawe, K-H John Ling, and Anita Mathias
Gilead Sciences, Foster City, CA
|
| |
|
|
|
|
|
